NCT03920618View on ClinicalTrials.gov

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 21, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Hepatitis BAcute-On-Chronic Liver Failure
Interventions
DRUG

Entecavir

Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.

DRUG

Tenofovir Disoproxil Fumarate

Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.

DRUG

Tenofovir Alafenamide

Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.

Trial Locations (1)

510630

RECRUITING

Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER